capecitabine has been researched along with taxane in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 21 (37.50) | 29.6817 |
| 2010's | 30 (53.57) | 24.3611 |
| 2020's | 4 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Horii, I; Ishitsuka, H; Shimma, N | 1 |
| Gershanovich, ML; Semiglazova, TIu | 1 |
| Ball, ED; Bashey, A; Corringham, S; Jones, V; Lancaster, D; Law, P; Silva-Gietzen, J; Sundaram, S | 1 |
| Maher, JF; Villalona-Calero, MA | 1 |
| Ilersich, AL; Verma, S | 1 |
| Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G | 1 |
| Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E | 1 |
| Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA | 1 |
| Atkinson, N; Bodurka, DC; Branham, D; Gershenson, DM; Jenkins, AD; Sun, CC; Verschraegen, C; Wolf, JK | 1 |
| Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC | 1 |
| Chan, A; Gelmon, K; Harbeck, N | 1 |
| Joensuu, H; Kellokumpu-Lehtinen, PL; Lehtinen, I; Sjöström-Mattson, J; Sunela, K | 1 |
| Amare, M; Asmar, L; Blum, JL; Dees, EC; Gill, DP; Ilegbodu, D; McMahon, RT; O'Shaughnessy, JA; Vukelja, SJ | 1 |
| Clemons, M; Dranitsaris, G; Joy, A; Mackey, J; Trudeau, M; Verma, S; Wong, NS | 1 |
| Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K | 1 |
| Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B | 1 |
| Basaran, G; Blot, E; Bogaerts, J; Cameron, D; Canney, P; Coleman, R; Cufer, T; Ellis, P; Marreaud, S; Pajk, B; Piccart, M; Vermorken, J | 1 |
| Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L | 1 |
| Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N | 1 |
| Hatake, K; Ito, Y; Iwase, T; Osaki, Y; Sugihara, T; Takahashi, S; Tokudome, N | 1 |
| Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA | 1 |
| Castaneda, CA; Gómez, HL | 1 |
| Kohles, J; Rugo, HS; Schulman, KL | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Fan, Y; Wang, J; Xu, B | 1 |
| Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P | 1 |
| Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Lee, KS; Nam, BH; Park, IH; Ro, J | 1 |
| Amler, L; Girish, S; Guardino, E; Krop, IE; LoRusso, P; Lu, M; Miller, KD; Modi, S; Rodriguez, G; Rugo, HS; Winer, EP; Yardley, D; Zheng, M | 1 |
| Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N | 1 |
| Gligorov, J; Joensuu, H | 1 |
| Delozier, T; Ettl, J; Finek, J; Glogowska, I; Kilar, E; Malamos, N; Palomo, AG; Sommer, H; Torrecillas, L; Vega, JM | 1 |
| Dirix, LY; Dirix, M; Huget, P; Rutten, A | 1 |
| Cao, R; Liu, C; Liu, XH; Man, YN; Wu, XZ | 1 |
| Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Awada, A; Cortes, J; He, Y; Kaufman, PA; Olivo, M; Twelves, C; Vahdat, L | 1 |
| Cao, J; Hu, X; Liu, Z; Lv, F; Shao, Z; Wang, B; Wang, L; Wang, Z; Zhang, J; Zhang, S; Zhao, X | 1 |
| Ahn, JS; Choi, MK; Hong, JY; Im, YH; Jung, HA; Lee, SJ; Park, YH | 1 |
| Ahn, JS; Awada, A; Cortes, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Cai, R; Du, F; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
| Kim, HH; Lee, J; Ro, SM; Yang, JH | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Carey, LA | 1 |
| Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
| Aapro, M; Bondarenko, I; Campone, M; Krishnamurthy, S; Lebedeva, L; Martin, M; Roman, L; Sakaeva, D; Vedovato, JC | 1 |
| Ahn, JH; Im, SA; Jung, KH; Kim, HJ; Kim, JH; Kim, SB; Kim, TY; Lee, KH; Lee, KS; Lee, S; Nam, BH; Park, IH; Park, KH; Park, YH; Ro, J; Sim, SH; Sohn, JH | 1 |
| Blair, HA | 1 |
| Jiang, Z; Lan, L; Li, L; Pan, Z; Yang, Y; Yue, Z | 1 |
| Ding, T; Dong, L; Gu, XS; Li, JB; Ma, C; Xie, BJ; Zhu, LN; Zhu, ZN | 1 |
| Li, Y; Lin, Y; Mao, F; Shen, S; Sun, Q; Zhang, X; Zhou, Y | 1 |
| Abdi, A; Alsaloumi, L; Basgut, B; Shawagfeh, S | 1 |
| Drier, SW; Ekwueme, DU; Fairley, TL; Gogate, A; Reeder-Hayes, KE; Rocque, GB; Rotter, J; Trogdon, JG; Wheeler, SB | 1 |
11 review(s) available for capecitabine and taxane
| Article | Year |
|---|---|
[Discovery and development of novel anticancer drug capecitabine].
Topics: Animals; Antineoplastic Agents; Biological Availability; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Design; Fluorouracil; Humans; Liver; Mice; Neoplasms; Taxoids; Thymidine Phosphorylase; Up-Regulation | 1999 |
Taxanes and capecitabine in combination: rationale and clinical results.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Fluorouracil; Humans; Paclitaxel; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2002 |
The role of capecitabine in first-line treatment for patients with metastatic breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Taxoids | 2006 |
Adjuvant treatments for triple-negative breast cancers.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Methotrexate; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Treatment Outcome | 2012 |
Trastuzumab emtansine in breast cancer.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Immunoconjugates; Lapatinib; Maytansine; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2013 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
Pyrotinib: First Global Approval.
Topics: Acrylamides; Aminoquinolines; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids | 2018 |
Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Incidence; Neoplasm Grading; Progression-Free Survival; Taxoids; Treatment Outcome | 2018 |
A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Humans; Molecular Targeted Therapy; Network Meta-Analysis; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Treatment Outcome | 2020 |
Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Staging; Prognosis; Retreatment; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Female; Hand-Foot Syndrome; Humans; Middle Aged; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2020 |
26 trial(s) available for capecitabine and taxane
| Article | Year |
|---|---|
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Budgets; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Metastasis; Ontario; Paclitaxel; Population Surveillance; Survival Analysis; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine; Women's Health | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prodrugs; Taxoids; Treatment Outcome | 2004 |
A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids | 2006 |
Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2006 |
A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Prodrugs; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Middle Aged; Paclitaxel; Taxoids | 2007 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2007 |
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Drug Tolerance; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2008 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Drug Costs; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Taxoids | 2009 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; China; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Epothilones; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Prospective Studies; Taxoids; Treatment Outcome | 2012 |
Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Taxoids; Treatment Outcome | 2013 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Immunotoxins; Lapatinib; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Fatigue; Female; Fever; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Remission Induction; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Furans; Humans; Ketones; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids | 2014 |
Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Hemagglutinins; Humans; Mannose; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pseudomonas aeruginosa; Receptor, ErbB-2; Safety; Salvage Therapy; Taxoids; Young Adult | 2015 |
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Middle Aged; Neoplasm Staging; Physicians; Polyethylene Glycols; Taxoids | 2015 |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Chemotherapy-Induced Febrile Neutropenia; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Progression-Free Survival; Quality of Life; Survival Analysis; Taxoids; Vinblastine | 2018 |
Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Drug Administration Schedule; Female; Humans; Irinotecan; Middle Aged; Progression-Free Survival; Quality of Life; Taxoids; Treatment Outcome | 2019 |
19 other study(ies) available for capecitabine and taxane
| Article | Year |
|---|---|
[Xeloda (capecetabine) in the treatment of disseminated breast cancer after failure with anthracyclines and taxanes].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Staging; Taxoids; Treatment Failure; Treatment Outcome | 2001 |
Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Transplantation, Autologous; Treatment Outcome | 2001 |
Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab | 2007 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pleural Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2009 |
Prolonged disease control in a patient with anthracycline- and taxane-resistant breast cancer.
Topics: Adult; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epothilones; Female; Fluorouracil; Humans; Taxoids; Treatment Outcome | 2009 |
Cost comparison of capecitabine in patients with breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Cost of Illness; Cost Savings; Cost-Benefit Analysis; Databases, Factual; Deoxycytidine; Drug Costs; Female; Fluorouracil; Humans; Middle Aged; Retrospective Studies; Taxoids; United States | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2011 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Hematologic Diseases; Humans; Middle Aged; Patient Compliance; Retrospective Studies; Severity of Illness Index; Taxoids; Vinblastine; Vinorelbine | 2012 |
Individualized chemotherapy based on organ selectivity: a retrospective study of vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Middle Aged; Organoplatinum Compounds; Precision Medicine; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Health Care Costs; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2014 |
Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2015 |
[Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Humans; Neutropenia; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
[Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Leukopenia; Neutropenia; Prospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neutropenia; Receptor, ErbB-2; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
De-escalating and escalating systemic therapy in triple negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm, Residual; Platinum Compounds; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden | 2017 |
Cost-Effectiveness of Pharmacologic Treatment Options for Women With Endocrine-Refractory or Triple-Negative Metastatic Breast Cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carboplatin; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Paclitaxel; Quality of Life; Taxoids | 2023 |